Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
The Body Covers:
The XIII International AIDS Conference
Durban, South Africa

July 9-14, 2000



The XIII International AIDS Conference took place in Durban, South Africa from July 9-14, 2000. The Body was pleased to provide coverage of this important conference. Covering the conference for The Body were some of the leading HIV specialists in the United States. They have helped put in perspective the hundreds of reports coming out of Durban. Among the doctors providing coverage were Cal Cohen, M.D., Ann Collier, M.D., Judith Currier, M.D., Judith Feinberg, M.D., Alvan Fisher, M.D., and Pablo Tebas, M.D.

12,000 people from all over the world attended the conference, including an immense assortment of people involved in HIV/AIDS care or prevention. Those attending included scientists and clinicians, health care workers, public health agencies, people living with AIDS, AIDS non-governmental organizations (NGOs), AIDS services organizations (ASOs) and the media. Since 1985, the International AIDS Conference has taken place regularly -- it now takes place every two years.

The theme of this year's conference was "Break The Silence," which the conference coordinators refer to as the urgent need to break the silence on equal access to treatment and care; improved and ongoing prevention of HIV transmission; governmental and private sector support of HIV education and resources; human rights; access of appropriate and meaningful information to all sectors and ensuring a supportive environment for people living with HIV/AIDS (PWA) in society.

This theme was particularly appropriate this year as Sub-Saharan Africa continues to have the largest number of people living with HIV -- each day about 1,500 people in South Africa are infected with HIV. Thus one focus of this year's conference in South Africa was the crucial need for response to the epidemic in South Africa and other developing countries around the world.

Funding for this conference coverage at The Body was provided, in part, by unrestricted educational grants from Agouron Pharmaceuticals, Inc., Bio-Technology Group Corp., DuPont Pharmaceuticals Company, Glaxo Wellcome, Ortho Biotech Inc., and Roxane Laboratories, Inc.



The Body's Conference Summaries
Day One
Monday,
July 10
Day Two
Tuesday,
July 11
Day Three
Wednesday,
July 12
Day Four
Thursday,
July 13
Opening Ceremony
(Sunday, July 9)

Plenary: The Jonathan Mann Memorial Lecture
(Sunday, July 9)

Anemia and HIV

Men Who Have Sex With Men

Patient Adherence to Antiretroviral Therapies -- I

Animal Models -- Interventions

Symposium: The Science of HIV/AIDS -- Evolution & Impact

Symposium: Management of Drug Resistance

Male Circumcision: An Ignored Intervention

Plenary Session: Living with AIDS

Post-Exposure Prophylaxis (PEP)

New Antivirals/Targets

Adherence to Antiretroviral Therapy -- Why So Low?

The Prevalence of Hypogonadism in HIV-Infected Patients Receiving HAART

Behavioral Predictors and Outcomes of HAART

Attempts at Simplifying Treatment Regimens

ARV Clinical Trials -- II

More on Salvage Studies

Safety and Efficacy of Abacavir and Efavirenz

Mitochondrial Toxicity

Debate: Affordable Drugs, Antiretroviral Therapy

Reverse Transcriptase Mutation Patterns from ZDV-Naïve Subjects Failing d4T-Containing Regimens

Pharmacokinetics of Amprenavir in Combination with Efavirenz or Delavirdine in HIV-Infected Children

Therapeutic Drug Monitoring of Amprenavir Combined with Ritonavir as Salvage Therapy in HIV-1-Infected Patients

HIV-Related Malignancies

Post Sexual-Exposure Prophylaxis with HAART After Sexual Assaults

Sustained Virologic Suppression in Subjects Switched from Protease Inhibitors to Nevirapine

The Combination of Ritonavir and Amprenavir in Salvage Regimens Overcomes Clinically Multiple-Drug-Resistant HIV

Hormones and Body Composition

New Antiretrovirals -- I

Switching Antiretroviral Regimens

Co-Infection of HIV and Hepatitis Viruses

Emergence of Drug Resistance in the Treatment-Naïve Population

Lipodystrophy and Quality of Life

Switching Protease Inhibitor to Nevirapine Leads to Reversal of Hyperlipidemia and Lipodystrophy

The Cost of Managing Abnormal Fat Distribution and Metabolic Abnormalities in France

Clinical Trials of Antiretroviral Therapy

Responses to Salvage Combination Therapy with Efavirenz in Patients with HIV Who Have Failed Antiretroviral Therapy with a Protease Inhibitor

Prospective, Multicenter Study of ddI + Hydroxyurea + Efavirenz + Protease Inhibitor Salvage Therapy

Virologic Response to Indinavir, Efavirenz, and Adefovir Among Patients Failing Nelfinavir

Management of HIV Disease in Real Life

Abacavir, Lamivudine, and Efavirenz

Nelfinavir vs. Indinavir

Response to Salvage with Efavirenz: Implications for Sequencing Antiretroviral Therapy

Incidence and associations of fatigue in HIV-infected persons

Symposium: Issues in Antiretroviral Treatment

Development of Resistance to Stavudine (d4T) in Patients Who Fail on d4T-Containing Regimens

Patient Adherence with Twice-Daily Dosing of Nelfinavir Equivalent to NNRTIs When Given in Combination with Dual NRTIs

Study of Adherence to HAART in a Sample of HIV-Infected Patients

Lipodystrophy: Definition and Treatment

Self-Efficacy: Predictor of Adherence to Antiretroviral Medications

Hepatitis C and HIV Co-Infection: Clinical Aspects

Management of Drug Resistance

Does Optimism about HIV Treatment Lead to Riskier Sexual Behavior?

Forty-Eight-Week Analysis of Patients Receiving T-20 as a Component of Multi-Drug Salvage

Drug Interruptions, Holidays and Pauses: An Overview of Outcomes

Short Cycle Intermittent HAART: A Pilot Study

The Swiss-Spanish Intermittent Trial (SSITT)

The One-Year Safety and Efficacy Data of the HIVNET 012 Trial

Genotypic Resistance Analysis in Women Participating in PACTG 316 with HIV-1 Subtype E Subjects Using LIPA Assay

Drug Resistance in Mother-to-Child HIV Transmission

Bones and Nails

Closing Ceremony


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement